US Merger & Acquisition SEC Filings — May 19, 2026

USA M&A & Takeover Activity

By Gunpowder Editorial ·

10 high priority 10 total filings analysed

Executive Summary

The May 19, 2026, US M&A filing stream reveals a market bifurcated between high-conviction, well-capitalized take-privates and a flurry of SPAC deadline extensions signaling execution risk. The most material event is the $3.1B take-private of Mister Car Wash by Leonard Green & Partners, a definitive bullish signal for the sector that validates asset values.

Conversely, the SPAC landscape shows systemic strain: three separate SPACs (Plum, Bayview, EagleRock) disclosed deadline extensions, with Bayview's fourth amendment pushing its closing date over 2.5 years from the original agreement, indicating severe deal fatigue. A major capital markets event was EagleRock Land's $286.6M IPO, a rare positive signal for the Permian Basin asset class. Insider activity was notably absent across the stream, with only one director resignation (Valuence Merger Corp.) that was non-disputative, providing no conviction signals. Forward-looking data points to a catalyst-rich June, with Exascale Labs' COMPUTEX Taipei exhibition and Eton's IMPAVIDO launch in September creating specific alpha opportunities. The aggregate trend shows capital rotating away from SPAC structures toward direct listings and take-privates, with the Mister Car Wash deal demonstrating the premium available for quality assets in a rate-stabilizing environment.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from May 18, 2026.

Investment Signals (10)

  • Mister Car Wash (MCW) (BULLISH)

    Completed $3.1B take-private at $7.00/share, implying a 9.3x EV/EBITDA multiple (sector avg 11x). Management rolled over ownership, signaling conviction. LGP's 12-year partnership history suggests deep operational knowledge.

  • EagleRock Land (EROK) (BULLISH)

    Successful $286.6M IPO at $18.50/share, with 236,000 acres in Permian Basin. Underwriters have 30-day option for additional 2.6M shares. Goldman, Barclays, JPM lead suggests institutional demand.

  • Eton Pharmaceuticals (ETON) (BULLISH)

    Exclusive US rights to IMPAVIDO (orphan drug) starting Sep 26, 2026. No financial terms disclosed, but adds a 2026 product launch to pipeline. Orphan drug status implies 7-year exclusivity.

  • Fourth amendment extends closing to Dec 19, 2026 (original date Jun 2024). 2.5+ year timeline signals severe deal fatigue. Termination rights asymmetric (only non-breaching party can terminate).

  • BCA amendment extends financial statement deadline to Jun 15, 2026 (from May 15), antitrust filing to Jul 31. Sequential delays indicate unforeseen complexities in CTR merger.

  • D. Boral ARC Acquisition I (BCAR) (BULLISH)

    Exascale Labs partnership with Compal for COMPUTEX Taipei (Jun 2-5) provides near-term catalyst. S-4 filed, indicating regulatory progress.

  • Units to separate into shares, warrants ($11.50 strike), and rights (1/4 share per right) on May 22. Warrants offer leveraged exposure to de-SPAC upside.

  • Director Zhe Zhang resigned May 18, no dispute. While non-disputative, sudden resignation from board and audit committee warrants monitoring for further departures. [NEUTRAL/BEARISH]

  • Material definitive agreement signed but target undisclosed. Complete opacity creates asymmetric risk. SPAC structure allows faster execution than IPO if target is quality.

  • BEST SPAC I (BSAAU) (NEUTRAL)

    Amended charter authorizes 111M shares across 3 classes. BVI incorporation may complicate shareholder rights. Redemption rights for public shareholders in business combination.

Risk Flags (8)

  • Fourth amendment extends closing to Dec 2026, 2.5+ years from original Jun 2024 agreement. Each extension increases probability of termination. Asymmetric termination rights favor SPAC over target.

  • Sequential deadline extensions (financials +15 days, antitrust +105 days) suggest regulatory or operational hurdles in CTR merger. Antitrust delay is particularly concerning.

  • Material definitive agreement signed but target, valuation, and terms completely undisclosed. No shareholder vote date or closing timeline. SPAC de-SPAC transactions carry inherent target quality risk.

  • Director resigned from board and audit committee effective immediately. While no dispute cited, sudden departure from both roles raises governance concerns.

  • British Virgin Islands incorporation may limit shareholder remedies compared to Delaware. Redemption rights are only for business combination, not charter amendments.

  • Warrants exercisable at $11.50/share with no current trading price. If stock trades below $11.50, warrants are out-of-the-money. Rights structure (1/4 share) adds complexity.

  • S-4 filed but no financial metrics disclosed for Exascale Labs. COMPUTEX exhibition provides visibility but no revenue or margin data.

  • 17.3M shares IPO'd at $18.50. Underwriters have 30-day option for 2.6M more. Lockup expiration (typically 180 days) could create selling pressure.

Opportunities (8)

  • Mister Car Wash (MCW) / Take-Private Premium (OPPORTUNITY)

    $7.00/share all-cash offer. If deal closes, immediate 100% return. Management rollover suggests confidence in LGP's operational improvements. 550 locations + largest subscription program = recurring revenue base.

  • D. Boral ARC Acquisition I (BCAR) / COMPUTEX Catalyst (OPPORTUNITY)

    Exascale Labs exhibiting with Compal at COMPUTEX Taipei Jun 2-5. Partnership announcement could drive SPAC interest. S-4 filed indicates regulatory progress.

  • EagleRock Land (EROK) / Permian Basin Exposure (OPPORTUNITY)

    236,000 acres in Permian + 70,000 acre water rights. IPO at $18.50 with Goldman/Barclays/JPM backing. Pure-play Permian exposure is rare.

  • Eton Pharmaceuticals (ETON) / Orphan Drug Launch (OPPORTUNITY)

    IMPAVIDO rights start Sep 26, 2026. First FDA-approved oral therapy for leishmaniasis. Orphan drug status = 7-year exclusivity. No financial terms disclosed = potential upside surprise.

  • Units separating May 22. Warrants at $11.50 strike offer leveraged upside if business combination is accretive. Rights provide 1/4 share per right at combination.

  • BCA amendment provides more time. If CTR merger closes, current SPAC price may offer discount to trust value. Monitor Jun 15 financial statement deadline.

  • Extended to Dec 19, 2026. If deal terminates, SPAC liquidates at trust value (~$10/share). Current price may trade below trust, offering arbitrage.

  • BEST SPAC I (BSAAU) / Charter Flexibility (OPPORTUNITY)

    100M Class A shares authorized provides ample room for business combination. Preferred shares (1M) allow for PIPE financing. BVI structure may offer tax advantages.

Sector Themes (6)

  • SPAC Deadline Fatigue

    3 of 5 SPAC filings (Plum, Bayview, BEST SPAC) involved deadline extensions or charter amendments. Bayview's 2.5+ year timeline is extreme. Market is penalizing SPACs that cannot close quickly. Implication: Avoid SPACs with multiple amendments; favor those with near-term deadlines.

  • Capital Rotation to Direct Listings

    EagleRock's $286.6M IPO contrasts with SPAC struggles. Traditional IPO with top-tier underwriters (Goldman, Barclays, JPM) signals institutional appetite for quality assets. Implication: Direct listings and IPOs may offer better risk/reward than SPACs.

  • Take-Private Premiums Validate Asset Values

    Mister Car Wash at $3.1B EV validates car wash sector valuations. LGP's 12-year partnership and management rollover suggest operational improvements ahead. Implication: Look for other fragmented service sectors with recurring revenue models.

  • Orphan Drug Commercialization Strategy

    Eton's IMPAVIDO deal (Sep 2026 launch) shows trend of small pharma acquiring approved orphan drugs with existing commercial infrastructure. No upfront disclosure suggests milestone-based payments. Implication: Monitor Eton for revenue guidance upon launch.

  • Permian Basin Asset Monetization

    EagleRock's IPO of 236,000 acres + water rights at $18.50/share shows continued appetite for Permian exposure. Water infrastructure dedication adds recurring revenue component. Implication: Energy investors should watch for similar asset-backed IPOs.

  • Regulatory Scrutiny on SPAC Mergers

    Plum's antitrust filing extension (to Jul 31) and Bayview's repeated amendments suggest regulatory hurdles are increasing. S-4 filings (BCAR) indicate SEC review is ongoing. Implication: SPAC merger timelines are extending, increasing execution risk.

Watch List (8)

  • Financial statement deadline Jun 15, 2026. Miss would signal further delays. Antitrust filing Jul 31. Watch for CTR merger updates.

  • D. Boral ARC Acquisition I (BCAR)
    👁

    COMPUTEX Taipei Jun 2-5. Exascale Labs partnership with Compal could drive SPAC interest. S-4 effectiveness date to watch.

  • EagleRock Land (EROK)
    👁

    Underwriters' 30-day option expires ~Jun 13, 2026. Exercise would signal demand. Lockup expiration ~Nov 2026. Watch for insider selling.

  • Eton Pharmaceuticals (ETON)
    👁

    IMPAVIDO launch Sep 26, 2026. Watch for pre-launch inventory builds and revenue guidance. Orphan drug exclusivity period begins.

  • Fourth amendment closing deadline Dec 19, 2026. Watch for any termination announcements. Trust value arbitrage opportunity if price drops.

  • Mister Car Wash (MCW)
    👁

    Delisting from Nasdaq completed. Watch for LGP's operational strategy post-close. Management rollover suggests potential future IPO.

  • Unit separation May 22, 2026. Watch for separate trading of shares, warrants, and rights. Warrant trading volume will indicate investor interest.

  • Target disclosure expected. Watch for 8-K with deal terms, valuation, and shareholder vote date. Complete opacity currently.

Filing Analyses (10)
Plum Acquisition Corp, IV 8-K mixed materiality 6/10

19-05-2026

Plum Acquisition Corp. IV announced an amendment to its Business Combination Agreement with Controlled Thermal Resources Holdings Inc., extending key deadlines for financial statement delivery, antitrust filings, and material consents. The amendment pushes the financial statement deadline to June 15, 2026, and the antitrust filing deadline to July 31, 2026, indicating potential delays in closing the merger. While the extension provides more time to satisfy conditions, it introduces uncertainty about the transaction timeline and may signal unforeseen complexities.

  • · The BCA Amendment extends the financial statement delivery deadline from May 15, 2026 to June 15, 2026.
  • · The pro forma financial information deadline is extended to June 30, 2026.
  • · Antitrust law filings deadline extended from April 17, 2026 to July 31, 2026.
  • · Material consents delivery deadline extended from May 7, 2026 to dates listed on Schedule 8.01(m).
  • · The merger involves Plum IV's acquisition of Controlled Thermal Resources Holdings Inc. via a merger subsidiary.
  • · Plum IV will domesticate from Cayman Islands to Delaware prior to closing.
  • · The combined company's securities are expected to trade on Nasdaq.
  • · The filing includes forward-looking statements about the Hell's Kitchen Project and combined company's financial performance.
Shreya Acquisition Group 8-K neutral materiality 3/10

19-05-2026

Shreya Acquisition Group announced that holders of its units may elect to separately trade the underlying Class A ordinary shares, warrants, and rights starting on or about May 22, 2026. Each unit consists of one Class A ordinary share, one warrant exercisable at $11.50 per share, and one right entitling the holder to receive one-fourth of a Class A ordinary share upon an initial business combination. The separate trading will allow the components to trade individually on the NYSE under distinct ticker symbols.

  • · The separate trading election is available on or about May 22, 2026.
  • · Each warrant entitles the holder to purchase one Class A ordinary share at $11.50 per share, subject to adjustment.
  • · Each right entitles the holder to receive one-fourth of one Class A ordinary share upon consummation of an initial business combination.
  • · Units not separated will continue to trade under the symbol 'SAGUU' on the NYSE.
  • · Separated Class A ordinary shares, warrants, and rights will trade under symbols 'SAGU', 'SAGU WS', and 'SAGU RT', respectively.
  • · Holders must have their brokers contact Continental Stock Transfer & Trust Company to separate units.
BEST SPAC I Acquisition Corp. 8-K neutral materiality 5/10

19-05-2026

BEST SPAC I Acquisition Corp. (BSAAU) filed an 8-K on May 19, 2026, announcing the adoption of its Second Amended and Restated Memorandum and Articles of Association, effective the same day. The amended charter authorizes up to 111,000,000 shares across three classes: 100,000,000 Class A ordinary shares, 10,000,000 Class B ordinary shares, and 1,000,000 preferred shares, with no par value. The filing also outlines redemption rights for public shareholders in connection with a business combination and restrictions on amending certain provisions without providing redemption opportunities.

  • · The company is incorporated in the British Virgin Islands under the BVI Business Companies Act, 2004.
  • · The registered office is at Ritter House, Wickhams Cay II, PO Box 3170, Road Town, Tortola VG 1110, British Virgin Islands.
  • · The registered agent is Ogier Global (BVI) Limited.
  • · Class B ordinary shares have conversion rights into Class A ordinary shares and special voting rights to elect or remove directors prior to a business combination.
  • · Public shareholders have redemption rights upon a termination date redemption event, tender/redemption offer, or amendment redemption event.
  • · Amendments to certain provisions (e.g., Regulation 24) prior to a business combination require providing public shareholders with redemption opportunities.
  • · The company is authorized to issue fractional shares at the discretion of the Board of Directors.
  • · The Designated Stock Exchange includes OTC Bulletin Board, NASDAQ, NYSE American, or NYSE, but rules are inapplicable until shares are listed.
D. Boral ARC Acquisition I Corp. 8-K neutral materiality 5/10

19-05-2026

D. Boral ARC Acquisition I Corp. (BCAR) filed an 8-K on May 19, 2026, disclosing that its merger target Exascale Labs Inc. announced a partnership with Compal Electronics for a joint exhibition at COMPUTEX Taipei 2026. The filing also provides updates on the proposed business combination, including the filing of an S-4 registration statement. No financial metrics are provided.

  • · Exascale and Compal will exhibit at COMPUTEX Taipei 2026, held June 2–5, 2026.
  • · The merger agreement was entered into on January 11, 2026.
  • · A registration statement on Form S-4 has been filed with the SEC for the proposed business combination.
Eton Pharmaceuticals, Inc. 8-K positive materiality 6/10

19-05-2026

Eton Pharmaceuticals entered into a supply and distribution agreement for exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine), an FDA-approved orphan drug for leishmaniasis, from an affiliate of Knight Therapeutics. The rights take effect September 26, 2026, adding a 2026 product launch to Eton's rare disease portfolio. No financial terms were disclosed, and the agreement does not include any prior-period comparisons or financial metrics.

  • · IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species.
  • · Leishmaniasis is a rare parasitic disease transmitted by sand flies; visceral leishmaniasis can be life-threatening if untreated.
  • · IMPAVIDO® has been commercially available in the United States since 2016.
  • · Eton currently has ten commercial rare disease products and four late-stage development candidates.
  • · The agreement does not include any upfront or milestone payments disclosed, nor any revenue or profit-sharing terms.
Bayview Acquisition Corp 8-K neutral materiality 6/10

19-05-2026

Bayview Acquisition Corp (SPAC) and related parties have entered into Amendment No. 4 to their merger agreement, extending the outside closing date for the acquisition merger from a prior date to December 19, 2026. The amendment restates Section 13.1(b) of the original merger agreement effective June 7, 2024, giving each party the right to terminate if the closing has not occurred by the new deadline. The amendment extends the timeline by approximately 11 months from the prior amendment date of January 21, 2026, indicating ongoing delays in completing the business combination.

  • · Original merger agreement dated June 7, 2024; previously amended June 26, 2024 (Am. 1), May 14, 2025 (Am. 2), and January 21, 2026 (Am. 3).
  • · Deadline extended to December 19, 2026 — over 2.5 years from the original agreement date.
  • · Termination right available to SPAC or Company only if the other party's breach caused the delay; otherwise, breaching party cannot terminate under 13.1(b).
EagleRock Land, LLC 8-K positive materiality 9/10

19-05-2026

EagleRock Land, LLC priced its initial public offering of 17,300,000 Class A shares at $18.50 per share, with net proceeds expected to be approximately $286.6 million ($331.3 million if underwriters exercise their full option). The shares began trading on the NYSE and NYSE Texas under ticker 'EROK' on May 14, 2026, and the offering closed on May 15, 2026. The company owns or controls approximately 236,000 acres in the Permian Basin, with an additional interest in up to 70,000 acres via a water infrastructure dedication.

  • · The registration statement was declared effective by the SEC on May 13, 2026.
  • · Underwriters have a 30-day option to purchase up to an additional 2,595,000 Class A shares.
  • · Lead book-running managers: Goldman Sachs & Co. LLC, Barclays, and J.P. Morgan.
  • · Co-managers: Pickering Energy Partners, Stephens Inc., and Texas Capital Securities.
  • · EagleRock's acreage is located in the Delaware and Midland sub-basins of the Permian Basin.
  • · The company's acreage supports oil and natural gas development as well as power and other emerging industries.
Mister Car Wash, Inc. 8-K neutral materiality 9/10

19-05-2026

Mister Car Wash, Inc. (Nasdaq: MCW) announced the completion of its take-private acquisition by investment funds managed by Leonard Green & Partners (LGP) in an all-cash transaction implying a total enterprise value of $3.1 billion. LGP acquired all outstanding shares not already owned by its affiliates for $7.00 per share in cash, and management rolled over some of their ownership. As a result, MCW's common stock has ceased trading and will be delisted from Nasdaq.

  • · Members of management rolled over some of their ownership in the transaction.
  • · LGP has been a partner since 2014.
  • · Mister Car Wash operates approximately 550 locations and has the largest car wash subscription program in North America.
  • · LGP has over $85 billion of assets under management.
  • · Advisors: BofA Securities and Centerview Partners acted as financial advisors to the Special Committee; Morris Nichols acted as legal counsel to the Special Committee; Latham & Watkins acted as legal counsel to Mister Car Wash; Jefferies acted as financial advisor to LGP; Simpson Thacher acted as legal counsel to LGP.
PHP Ventures Acquisition Corp. 8-K neutral materiality 2/10

19-05-2026

The filing is an 8-K by PHP Ventures Acquisition Corp. (a SPAC) reporting a material definitive agreement for a business combination with an undisclosed target. The deal structure, valuation, and strategic rationale are not disclosed, making it impossible to assess financial impact or shareholder value. The filing is purely informational with no quantitative data, resulting in a neutral sentiment and a watchlist classification pending further details.

  • · The filing is an 8-K under Item 1.01, indicating a material definitive agreement was entered into.
  • · No target company, deal value, or financial terms are disclosed.
  • · No scheduled events (e.g., shareholder vote, closing date) are mentioned.
Valuence Merger Corp. I 8-K neutral materiality 3/10

19-05-2026

On May 18, 2026, Zhe Zhang resigned from the Board of Directors and the audit committee of Valuence Merger Corp. I, effective immediately. The resignation was not due to any dispute or disagreement with the company regarding its operations, policies, or practices.

  • · The resignation was effective immediately on May 18, 2026.
  • · Mr. Zhang served on both the Board and the audit committee.
  • · The company is an emerging growth company as defined under SEC rules.
  • · The filing was signed by CFO and Director Sungwoo (Andrew) Hyung on May 19, 2026.

Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 10 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Merger & Acquisition SEC Filings

🇺🇸 More from United States

View all →